In November 2005, the US Food and Drug Administration (FDA) released a health advisory alerting the public to findings that show the use of long-acting β2 agonists could lead to a worsening of wheezing symptoms in some patients. Nowadays, available long-acting β2 agonists include salmeterol,<unk> , bambuterol, and sustained-release oral salbutamol. Combinations of inhaled steroids and long-acting bronchodilators are becoming more widespread – combination preparations include fluticasone/salmeterol and budesonide/formoterol.
Formoterol
Arformoterol
Salmeterol
Fluticasone
Levosalbutamol
Salbutamol
Beclometasone/formoterol
Seratrodast